Edward Schwarz, PhD, Founder and Chief Scientific Advisor
Telephus’ scientific founder is Dr. Edward Schwarz, a thought leader in the field of musculoskeletal health and the Richard and Margaret Burton Distinguished Professor in Orthopaedics in the Department of Orthopaedics at the University of Rochester School of Medicine and Dentistry. As Director of the Center for Musculoskeletal Research at the University of Rochester Medical Center, he has developed multiple proprietary preclinical models to study implant-associated osteomyelitis and other aspects of bone health and has pioneered immunotherapeutic approaches to treat bone inflammatory disease and other mechanisms driving skeletal erosion and inhibiting bone repair. A key opinion leader and consultant to major global pharmaceutical and biotechnology companies, Dr. Schwarz holds multiple patents in the areas of bone health and therapies for joint disease. Dr. Schwarz received his PhD in Immunology from the Albert Einstein College of Medicine, his BS in Biology from the Worcester Polytechnic Institute and completed his postdoctoral work at the Salk Institute.
Joseph Siletto, Business Advisor
Joseph Siletto is co-founder and CEO of Scion Medical Technologies, a global medical device company headquartered in Newton, Massachusetts with operations in both the US and China. He has been involved with over 100 public and private financing and M&A transactions in the life sciences sector as a banker and a principal investor. Prior to Scion, Mr. Siletto was a Director of Healthcare Investment Banking at Cowen and Company in Boston, a Principal and Co-Head of the Life Sciences Group at SVB Alliant, a boutique M&A advisory firm and a Vice President with Banc of America Securities in San Francisco. Mr. Siletto earned an MBA from the Haas School of Business at the University of California at Berkeley, and holds a BA from Duke University. He has also completed studies at the Beijing Language Institute and is fluent in Mandarin.
Jeff Stein, PhD, Business Advisor
Dr. Stein is currently President and Chief Executive Officer of Cidara Therapeutics. Previously, he was CEO of Trius Therapeutics, Inc., a publicly-traded pharmaceutical company, from its founding in 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from the U.S. Food and Drug Administration and is now marketed as Sivextro®. From 2005 to 2010, Dr. Stein was a venture partner at Sofinnova Ventures, a biotech venture capital fund. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer at Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein currently serves on the Board of Directors of Paratek Pharmaceuticals, a publicly-traded biopharmaceutical company. He was also founding Chairman and President of the Antibiotics Working Group, an industry led non-profit organization. Dr. Stein holds a B.S. in marine biology and an M.S. in biology from California State University, Long Beach, and a Ph.D. in marine biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology.